Search results
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for...
Zacks· 3 days agoFree Report) is predicted by Wall Street analysts to post quarterly earnings of $0.51 per share, reflecting an increase of 27.5% compared to the same period last year. Prior to a company's earnings ...
Teva to Present at the 2024 Bank of America Healthcare Conference
Morningstar· 4 days agoTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday ...
Generic Drug Giant Teva Hires New Legal Chief After DOJ Deal
Bloomberg Law· 6 days agoTeva Pharmaceutical Industries Ltd. has a new chief legal officer in David McAvoy, who succeeds David Stark as the top lawyer for the world’s largest generic drug manufacturer.
Pfizer to pay $25.5 mln to settle remaining Effexor XR antitrust claims
Reuters· 7 days agoPfizer has agreed to pay $25.5 million to resolve claims that its predecessor Wyeth conspired with...
Ozempic and 19 other drugs have 'junk' patents, the FTC says in a new challenge
Quartz· 6 days agoThe U.S. Federal Trade Commission (FTC) announced on Tuesday that it is disputing over 300 patent...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First...
Morningstar· 6 days agoAlvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. ...
Opioid Use Disorder Market Expected to Reach USD 6.15 Billion by 2030: SNS Insider
Digital Journal· 3 days agoThe global Opioid Use Disorder (OUD) market has witnessed significant growth in recent years, driven...
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Morningstar· 4 days agoTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets Teva’s 2023 Healthy Future Report highlights the Company’s renewed sustainability strategy, which guides Teva in addressing global challenges while also
US FDA approves Neurocrine Biosciences' movement disorder drug
Reuters· 4 days ago, opens new tab Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the ...
Israel stocks higher at close of trade; TA 35 up 1.32% By Investing.com
Investing.com· 6 days agoIsrael stocks higher at close of trade; TA 35 up 1.32%